Siow Ming Lee

Summary

Affiliation: University College London
Country: UK

Publications

  1. ncbi Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
    Martin F Muers
    Leeds General Infirmary, Leeds, UK
    Lancet 371:1685-94. 2008
  2. ncbi First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial
    Siow Ming Lee
    University College London Cancer Institute and University College London Hospitals, London, UK
    Lancet Oncol 13:1161-70. 2012
  3. ncbi Anti-angiogenesis drugs in lung cancer
    Siow Ming Lee
    University College London Hospital and UCL Cancer Institute, London, Department of Oncology, University College Hospital, London, UK
    Respirology 15:387-92. 2010
  4. ncbi Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer
    Siow Ming Lee
    University College Hospital, London, United Kingdom
    J Clin Oncol 27:5248-54. 2009
  5. ncbi Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial
    Siow Ming Lee
    Department of Oncology, University College Hospital, 250 Euston Road, London, UK
    J Natl Cancer Inst 101:1049-57. 2009
  6. ncbi Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer
    S M Lee
    Department of Oncology, University College Hospital, London, UK
    Thorax 64:75-80. 2009
  7. ncbi Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer
    Siow Ming Lee
    Department of Oncology, University College Hospital, 250 Euston Road, London NW1 2PG, UK
    Lung Cancer 59:364-8. 2008
  8. ncbi Tumor lysis syndrome after treatment with docetaxel for non-small-cell lung cancer
    Daniel Ajzensztejn
    Department of Oncology, The Whittington Hospital NHS Trust, London, United Kingdom
    J Clin Oncol 24:2389-91. 2006
  9. ncbi Thymic 18F-fluorodeoxyglucose uptake on positron emission tomography scanning after doxorubicin, bleomycin, vincristin and dacarbazine chemotherapy and highly-active antiretroviral therapy in HIV-associated Hodgkin's disease in an adult
    Siow Ming Lee
    AIDS 22:159-60. 2008
  10. ncbi Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors
    Malcolm Ranson
    Department of Medical Oncology, University of Manchester, UK
    Clin Cancer Res 12:1577-84. 2006

Collaborators

  • Allan Hackshaw
  • Allan Price
  • Paul Ellis
  • T Eisen
  • W Qian
  • A G Nicholson
  • John Anderson
  • M T Seymour
  • Nicholas Thatcher
  • P Jenkins
  • D Sebag-Montefiore
  • Michael H Cullen
  • M R Ranson
  • Giuseppe Giaccone
  • Martin F Muers
  • Daniel Ajzensztejn
  • Sharon Moat
  • Mark Walker
  • S R Muthuramalingham
  • Kathleen Fiddles
  • Alemr Kahsay
  • Catherine Williams
  • Anna Meakin
  • David Fyfe
  • Emma Richardson
  • Balinder Hans
  • P Cornes
  • Nigel Perry
  • J Tobias
  • David Ellis
  • Ania Jones
  • Michael Page
  • Vicki Saul
  • Hannah Brooks
  • Victoria Frost
  • Janet Ironside
  • Alison Tilley
  • Linda Johstone
  • Alison Brewster
  • David J Girling
  • David Ferry
  • Anthony Fennerty
  • Denise Wright
  • Heather Peterson
  • Ruth Whale
  • C G Price
  • Christine Harle
  • Lisa Swift
  • Helen Bridle
  • Vanda Carter
  • Judy Reilly
  • Keeley Anderson
  • Alison Robinson
  • Lyn Furber
  • John Roberts
  • Tracey Ford
  • Christine Whiting
  • Jackie Worville
  • Claire Spencer
  • Sara Erridge
  • Sue Knox
  • Gurjit Kaur
  • Elaine Barr
  • Nicola Groves
  • Pam Taylor Neale
  • Emma Jane Beer
  • Robert Owens
  • Joan E Oldman
  • Karen McAdam
  • Alan Hunter
  • Alison Armour
  • Verity King
  • John White
  • Sandra Tang
  • Diane McKenzie
  • June de la Rue
  • Peter Kirkbride
  • Gail Rowark
  • R B Kulkani
  • Jeremy Steele
  • Richard Ayres
  • Laura Harris
  • Bruce Burnett
  • Elaine Noon
  • Rita Mohan
  • Kate Hill
  • Julie Gwilt
  • Lety Bowden
  • Helen Winter
  • J Slattery

Detail Information

Publications10

  1. ncbi Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
    Martin F Muers
    Leeds General Infirmary, Leeds, UK
    Lancet 371:1685-94. 2008
    ..We investigated whether the addition of chemotherapy to ASC improved survival and quality of life...
  2. ncbi First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial
    Siow Ming Lee
    University College London Cancer Institute and University College London Hospitals, London, UK
    Lancet Oncol 13:1161-70. 2012
    ..We investigated whether erlotinib improves clinical outcome in these patients...
  3. ncbi Anti-angiogenesis drugs in lung cancer
    Siow Ming Lee
    University College London Hospital and UCL Cancer Institute, London, Department of Oncology, University College Hospital, London, UK
    Respirology 15:387-92. 2010
    ..In lung cancer the use of these drugs has resulted in both positive and negative studies. In this paper the pros and cons are presented. We hope that this information will help the physician in making a proper treatment choice...
  4. ncbi Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer
    Siow Ming Lee
    University College Hospital, London, United Kingdom
    J Clin Oncol 27:5248-54. 2009
    ..We hypothesized that thalidomide, an oral antiangiogenic agent, when combined with chemotherapy, and as maintenance treatment, would improve survival in patients with advanced non-small-cell lung cancer (NSCLC)...
  5. ncbi Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial
    Siow Ming Lee
    Department of Oncology, University College Hospital, 250 Euston Road, London, UK
    J Natl Cancer Inst 101:1049-57. 2009
    ..We evaluated thalidomide, an anti-angiogenic agent, when combined with chemotherapy and as maintenance treatment...
  6. ncbi Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer
    S M Lee
    Department of Oncology, University College Hospital, London, UK
    Thorax 64:75-80. 2009
    ..This non-inferiority design trial aimed to determine whether the combination of gemcitabine and carboplatin (GC) results in similar survival but is less toxic with better quality of life...
  7. ncbi Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer
    Siow Ming Lee
    Department of Oncology, University College Hospital, 250 Euston Road, London NW1 2PG, UK
    Lung Cancer 59:364-8. 2008
    ..Despite the high response rates achieved following standard chemotherapy for small-cell lung cancer (SCLC), the majority of patients will subsequently die from disease progression...
  8. ncbi Tumor lysis syndrome after treatment with docetaxel for non-small-cell lung cancer
    Daniel Ajzensztejn
    Department of Oncology, The Whittington Hospital NHS Trust, London, United Kingdom
    J Clin Oncol 24:2389-91. 2006
  9. ncbi Thymic 18F-fluorodeoxyglucose uptake on positron emission tomography scanning after doxorubicin, bleomycin, vincristin and dacarbazine chemotherapy and highly-active antiretroviral therapy in HIV-associated Hodgkin's disease in an adult
    Siow Ming Lee
    AIDS 22:159-60. 2008
  10. ncbi Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors
    Malcolm Ranson
    Department of Medical Oncology, University of Manchester, UK
    Clin Cancer Res 12:1577-84. 2006
    ..CONCLUSION: This first administration of lomeguatrib to man successfully established an oral ADD of lomeguatrib and identified a combination regimen with temozolomide suitable for future clinical evaluation...